Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal
Standard
Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal. / Windler, E; Zyriax, B-Chr.
In: ATHEROSCLEROSIS PLUS, Vol. 18, 05.2015, p. 176-179.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal
AU - Windler, E
AU - Zyriax, B-Chr
N1 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
PY - 2015/5
Y1 - 2015/5
N2 - Current guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS), of the American College of Cardiology and the American Heart Association (ACC/AHA), and of the International Atherosclerosis Society (IAS) are all based on the same body of evidence, but come to strikingly different conclusions with regard to lipid lowering therapy. While the ESC/EAS guidelines assign appropriate treatments to distinct lipid disorders, the ACC/AHA guidelines focus exclusively on evidence from randomized controlled trials for statins, but lack advice for those lipid disorders without evidence from randomized trials. Thus, evidence based medicine in its strict sense may leave a clinically significant gap. In striking contrast, the position paper of the IAS suggests the most advanced evidence-based innovative concept of a goal of one and the same healthy cholesterol level for anyone.
AB - Current guidelines of the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS), of the American College of Cardiology and the American Heart Association (ACC/AHA), and of the International Atherosclerosis Society (IAS) are all based on the same body of evidence, but come to strikingly different conclusions with regard to lipid lowering therapy. While the ESC/EAS guidelines assign appropriate treatments to distinct lipid disorders, the ACC/AHA guidelines focus exclusively on evidence from randomized controlled trials for statins, but lack advice for those lipid disorders without evidence from randomized trials. Thus, evidence based medicine in its strict sense may leave a clinically significant gap. In striking contrast, the position paper of the IAS suggests the most advanced evidence-based innovative concept of a goal of one and the same healthy cholesterol level for anyone.
KW - Anticholesteremic Agents/therapeutic use
KW - Biomarkers/blood
KW - Cholesterol, LDL/blood
KW - Down-Regulation
KW - Evidence-Based Medicine/standards
KW - Guideline Adherence/standards
KW - Humans
KW - Hypercholesterolemia/blood
KW - Practice Guidelines as Topic/standards
KW - Risk Factors
KW - Risk Reduction Behavior
KW - Treatment Outcome
U2 - 10.1016/j.atherosclerosissup.2015.02.027
DO - 10.1016/j.atherosclerosissup.2015.02.027
M3 - SCORING: Review article
C2 - 25936323
VL - 18
SP - 176
EP - 179
JO - ATHEROSCLEROSIS PLUS
JF - ATHEROSCLEROSIS PLUS
SN - 2667-0895
ER -